New treatment for kids with lasting ITP
Part of Blood & lymphatic clinical trials.
This trial tests a new approach for children ages 1 to 10 who have had ITP for 3–12 months. It aims to find a better way to manage the condition and improve platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 1 to 10 years old
- Diagnosed with persistent ITP lasting 3 to 12 months
- No previous use of thrombopoietin agonist drugs (medicines that boost platelet production)
- No history of severe allergic reaction to IVIG (intravenous immunoglobulin therapy)
- No history of bleeding inside the head (intracranial hemorrhage)
- No problems with getting IV access (easy-to-reach veins)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
This study tests a new combination of two medicines (ianalumab and eltrombopag) for children with a blood condition called ITP (low platelets causing bruising and bleeding) who haven't improved with steroids. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
Hear when a new Persistent Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.